Spruce Biosciences (SPRB) Non-Current Deffered Revenue (2023)
Spruce Biosciences (SPRB) posted quarterly Non-Current Deffered Revenue of $2.8 million for Q2 2023, down 26.62% quarter-over-quarter from $3.8 million in Q1 2023.
Spruce Biosciences (SPRB) Non-Current Deffered Revenue (2023) Analysis & Trends
Spruce Biosciences (SPRB) has reported Non-Current Deffered Revenue for 1 consecutive years, with $2.8 million the latest figure, recorded in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 147.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Spruce Biosciences | 119.20 Mn | 119.20 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 2.81 Mn |
| Mar 31, 2023 | 3.83 Mn |